Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.53 |
| ▸ | CA2 | P00918 | 18/20 | 0.50 |
| ▸ | CA9 | Q16790 | 11/20 | 0.35 |
| ▸ | CA12 | O43570 | 7/20 | 0.34 |
| ▸ | CA7 | P43166 | 5/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL8576481 | 0.86 | KDM4E (0.46) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL2714949 | 0.80 | CA1 (0.36) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL660656 | 0.80 | ALDH1A1 (0.38) | CA1CA2CA5ACA5BALDH1A1 | |
| Ether SCHEMBL9272834 | 0.78 | — | — | |
| Methanesulfonic Acid Methyl Ester SCHEMBL1185064 | 0.78 | TSHR (0.62) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL1469697 | 0.76 | CA1 (0.38) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL7490052 | 0.76 | CA1 (0.38) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL1807497 | 0.76 | CA1 (0.38) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL10340529 | 0.76 | CA1 (0.38) | CA1CA2ALDH1A1 | |
| Ether SCHEMBL27570944 | 0.76 | CA5A (0.43) | CA1CA2CA5ACA5BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082640-A1 | Use of cox-2 inhibitors for preventing immunodeficiency | LAURAS AS (NO) | 2004-04-29 | — | — | US | claimed |
| JP-2004510705-A | — | — | 2004-04-08 | — | — | JP | claimed |
| EP-1303265-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | Lauras AS (NO) | 2003-04-23 | — | — | EP | claimed |
| WO-2002007721-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | LAURAS AS (NO) | 2002-01-31 | — | — | WO | claimed |
| US-7790738-B2 | Methods of treating and preventing AIDS using of COX-2 inhibitors | LAURAS AS (NO) | 2010-09-07 | — | — | US | disclosed |
| US-20040082640-A1 | Use of cox-2 inhibitors for preventing immunodeficiency | LAURAS AS (NO) | 2004-04-29 | — | — | US | disclosed |
| EP-1303265-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | Lauras AS (NO) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002007721-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | LAURAS AS (NO) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082640-A1 | Use of cox-2 inhibitors for preventing immunodeficiency | PTGES2, PTGS2, NFATC1 | CA1 2625/4885CA2 960/4885CA9 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.